Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sensorion

< Previous 1 2 3 4 Next >
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
From Sensorion
Via Business Wire
Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025
From Sensorion
Via Business Wire
Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025
From Sensorion
Via Business Wire
Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director
From Sensorion
Via Business Wire
Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025
From Sensorion
Via Business Wire
Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences
From Sensorion
Via Business Wire
Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report
From Sensorion
Via Business Wire
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity
From Sensorion
Via Business Wire
Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial
From Sensorion
Via Business Wire
Sensorion Announces Its Participation in Several Investor Conferences to be Held in March
From Sensorion
Via Business Wire
Sensorion Announces Its Participation In Several Congresses To Be Held In March
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting
From Sensorion
Via Business Wire
Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial
From Sensorion
Via Business Wire
Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial
From Sensorion
Via Business Wire
Sensorion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sensorion
Via Business Wire
Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the 31st Annual Congress of the European Society of Gene and Cell Therapy and the Presentation of Several Posters on GJB2-GT
From Sensorion
Via Business Wire
Sensorion Announces Webconference for Retail Shareholders on October 10, 2024
From Sensorion
Via Business Wire
Sensorion Announces the Availability of its Half Year 2024 Report
From Sensorion
Via Business Wire
Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology
From Sensorion
Via Business Wire
Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris
From Sensorion
Via Business Wire
Sensorion Reports 2024 First Half Results and Highlights Recent Updates
From Sensorion
Via Business Wire
Sensorion Announces Its Participation in the 59th Annual Inner Ear Biology Workshop
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the World Congress of Audiology in September 2024 in Paris and will Lead a Symposium on Medical Advances in the Field of Hearing Loss
From Sensorion
Via Business Wire
Sensorion Announces its Participation in Stifel's Biotech Summer Summit
From Sensorion
Via Business Wire
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
From Sensorion
Via Business Wire
Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss
From Sensorion
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.